burlulipase
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01710644)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lysosomal acid lipase/cholesteryl ester hydrolaseSupplementation
LIPA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- burlulipase
- burlulipase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01710644 | Phase 1/Phase 2 (Phase 2) | May 1, 2013 | Nordmark Arzneimittel GmbH & Co. KG, Parexel, University of Cincinnati |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nordmark Arzneimittel GmbH & Co. KG | For profit | 1 | 1 | 1 | 2013 |
| Parexel | For profit | 1 | 0 | 1 | 2013 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1